Regulatory Relief To Promote Domestic Production of Critical Medicines
May 8, 2025
May 8, 2025
Summary
Reduces rules and speeds up approvals to help more essential medicines be made in the United States instead of other countries.
What problem does this solve?
It takes too long, sometimes 5 to 10 years, to build medicine factories in the U.S. because of many different federal, state, and local rules. This order solves the problem by telling government agencies to remove unneeded rules and speed up the approval process for building these factories.
Who does this affect?
- Pharmaceutical manufacturers
- American patients
- Federal regulatory agencies
What does this order do?
Reference
Text:
Section:
Header:
Streamlining review of domestic pharmaceutical manufacturing by the food and drug administration
Speeds up FDA review for new medicine factories
Requires the Food and Drug Administration (FDA) to review its rules to get rid of unnecessary steps and make the approval process for new domestic drug manufacturing faster and more predictable.
Reference
Text:
Section:
Header:
Enhancing inspection of foreign manufacturing facilities
Increases checks on foreign medicine factories
Directs the FDA to improve its inspection system for overseas drug factories and to charge foreign facilities higher fees to pay for these checks.
Reference
Text:
Section:
Header:
Streamlining review of domestic pharmaceutical manufacturing by the environmental protection agency
Simplifies environmental rules for drug manufacturing
Tells the Environmental Protection Agency (EPA) to update its rules to remove duplicate requirements and speed up the review process for new pharmaceutical factories.
Reference
Text:
Section:
Header:
Centralized coordination of environmental permits to expand domestic pharmaceutical manufacturing capacity
Creates a single contact for environmental permits
Makes the EPA the main agency for handling environmental permits for new drug factories and requires a single point of contact to help applicants through the process.
Reference
Text:
Section:
Header:
Streamlining review of domestic pharmaceutical manufacturing by the united states army corps of engineers
Reviews water-related permits for factories
Orders the U.S. Army Corps of Engineers to see if a new, specific permit is needed to make it easier for drug manufacturing facilities to get approvals related to water.
What is the real world impact?
•
Could weaken safety and environmental rules
Critics might argue that fast-tracking approvals and removing regulations could lead to lower safety standards or harm the environment, as agencies are pushed to prioritize speed over careful review.
•
Reduces reliance on foreign countries for medicine
Aims to strengthen national security by ensuring the U.S. can produce its own essential medicines, especially during health emergencies, without depending on other nations.
•
Boosts the U.S. economy and creates jobs
Encourages investment in American manufacturing by making it faster and more predictable to build new facilities, which can lead to economic growth and new jobs in the pharmaceutical industry.
When does this start?
This order sets several deadlines for government agencies, starting from its signing date of May 5, 2025.
Reference
Text:
Section:
Header:
Enhancing inspection of foreign manufacturing facilities
Improved foreign factory inspections
Within 90 days, the FDA must develop improvements to its inspection plan for overseas drug manufacturing facilities.
Reference
Text:
Section:
Header:
Streamlining review of domestic pharmaceutical manufacturing by the food and drug administration
FDA rule review
Within 180 days, the FDA must review its existing regulations and take steps to remove unnecessary requirements for domestic drug manufacturing.
Reference
Text:
Section:
Header:
Streamlining review of domestic pharmaceutical manufacturing by the environmental protection agency
EPA rule review
Within 180 days, the EPA must take action to update its regulations to speed up the approval of new domestic drug manufacturing facilities.
Reference
Text:
Section:
Header:
Streamlining review of domestic pharmaceutical manufacturing by the united states army corps of engineers
Army corps of engineers permit review
Within 180 days, the Army Corps of Engineers must review its permits to see if a new permit is needed to help build pharmaceutical factories more efficiently.